论文部分内容阅读
活血通脉胶囊是用活血中药水蛭研制的一种新制剂,系中国人民解放军264医院水蛭科研组研制、由山西云中制药厂生产的抗动脉粥样硬化的新药物。经过11个医院大量的临床验证表明,本品治疗心绞痛的显效率为75％,甘油三酯(TG)下降率为92.97％。总胆固醇(TC)下降率为95.12％,使体内6—酮—前列腺素(6—K—PGF1α)水平明显上升,血栓素(TXB_2)明显下降,患者其它症状如胸闷(心悸、气短、头晕、头痛等在治疗后亦有70％以上病例获得好转。动物试验表明,活血通脉胶囊对高脂血症家兔不仅有效地降低了TC、TG、以及使6—酮—PGF1α上升,TXB_2下降,同时也减轻了冠状动脉、主动脉
Huoxue Tongmai Capsule is a new preparation developed from the traditional Chinese medicine Chinese medicine, Shuizhan. It is a new anti-atherosclerotic drug developed by the Shuizhan Research Group of the People’s Liberation Army 264 Hospital and manufactured by Shanxi Yunzhong Pharmaceutical Factory. After a large number of clinical trials in 11 hospitals, the apparent efficacy of this product in the treatment of angina was 75%, and the decrease rate of triglyceride (TG) was 92.97%. The decrease rate of total cholesterol (TC) was 95.12%, and the level of 6-keto-prostaglandin (6-K-PGF1α) in the body increased significantly, thromboxane (TXB_2) decreased significantly, and other symptoms such as chest tightness (palpitation, shortness of breath, dizziness, etc.) After treatment, more than 70% of the patients got headaches, and animal experiments showed that Huoxuetongmai Capsule not only effectively reduced TC, TG, but also increased 6-keto-PGF1α and decreased TXB_2 in rabbits with hyperlipidemia. Also reduces the coronary arteries, aorta